Early research reveals new clues to origin of diabetes

October 11, 2010

ANN ARBOR, Mich. - University of Michigan scientists have identified events inside insulin-producing pancreatic cells that set the stage for a neonatal form of non-autoimmune type 1 diabetes, and may play a role in type 2 diabetes as well. The results point to a potential target for drugs to protect normally functioning proteins essential for producing insulin.

A study published online today in the journal PLoS One shows that certain insulin gene mutations involved in neonatal diabetes cause a portion of the proinsulin proteins in the pancreas' beta cells to misfold. Proinsulin proteins are the precursors of insulin, which the body needs to regulate blood sugar levels. Crucially, the misfolded mutant proteins cause normal proinsulin proteins in beta cells to misfold as well, the scientists found in studies of mouse and rat beta cells.

"Once the 'good' proinsulin turns 'bad,' it cannot be made into insulin and so the beta cells, and then the whole animal, become insulin deficient. The insulin deficiency causes diabetes and from there, things get worse and worse," says Peter Arvan, M.D., Ph.D., the study's senior author. He directs the Michigan Comprehensive Diabetes Center and is William and Delores Brehm Professor and chief of Metabolism, Endocrinology and Diabetes at the U-M Medical School.


"We want to see how the mechanism we found in this rare form of neonatal diabetes applies to other forms of diabetes," says Ming Liu, M.D., Ph.D., the study's first author and a research assistant professor of internal medicine at the U-M Medical School.

Diabetes researchers know that protein misfolding in beta cells also occurs on a smaller scale in mice and people without diabetes, and at higher levels in type 2 diabetes, Arvan says. In type 2 diabetes, people develop reduced sensitivity to insulin, causing beta cells to work overtime and eventually fail. In non-autoimmune type 1, diabetes results when genetic mutations cause insufficient production of insulin from pancreatic beta cells.

"In all diabetes, beta cells don't perform to the level needed," says Arvan. "It's possible that the beta cell failure of type 2 diabetes also has a critical protein folding component," he says. "The question is, can you reach a point in ordinary diabetes where misfolding causes the problem we have identified?"

Research details

In lab dish cultures of normal rat and mice beta cells, the scientists introduced single gene mutations known to be involved in various types of neonatal diabetes. They consistently found that misfolding occurred in normal proinsulin protein when mutant proinsulin protein was present. They also observed the same aberrant events in the pancreatic beta cells of Akita mice, a mouse model with the same mutation that occurs in a human family with neonatal diabetes.


Proteins, which are molecules made of amino acids arranged in a certain order determined by genes, normally fold into specific shapes. But sometimes misfolding occurs. Protein folding is a phenomenon that has drawn a lot of recent attention from scientists who believe it plays a role in several common diseases.

Diabetes researchers currently lack a clear picture of why beta cells in the pancreas fail in diabetes. Many researchers look at stress and the stress response from the beta cells' endoplasmic reticulum or ER, a structure that transports materials within the cell. Stress in this structure occurs in diabetes, along with reduced beta cell mass.

Arvan and Liu found in the study that each of the mutations they examined led to ER stress and the ER stress response in beta cells, but that these ER events alone could not block insulin production in normal beta cells and do not appear to be the origin of the insulin deficiency. They hypothesize that protein misfolding events first block insulin production and cause insulin deficiency, leading to diabetes.

What's next

Uncovering the earliest events in the molecular mechanism of the disease may help diabetes researchers discover new therapies, the authors say. New drugs that could emerge would be at least several years away.

"It may be possible to find a way to modulate the environment in the endoplasmic reticulum to let the normal protein fold quickly, before the abnormal protein can act," says Liu.
Additional authors: Leena Haataja, Jordan Wright, U-M Medical School; Nalinda P. Wickramasinghe, Qing-Xin Hua, Nelson F. Phillips, Michael A. Weiss, Case Western Reserve University; Fabrizio Barbetti, University of Tor Vergata, Rome, Italy.

Funding: National Institutes of Health

Citation: PLoS One, http://dx.plos.org/10.1371/journal.pone.0013333


University of Michigan Health System

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.